Mycophenolate mofetil
Mycophenolate mofetil is an active ingredient of the class «immunosuppressive drug».
Chemical compound
Boxed warning (US label)
EMBRYOFETAL TOXICITY, MALIGNANCIES, and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations.
What it is used for
- Lipoid nephrosis
- Polymyositis
- Myasthenia gravis
- Lupus nephritis
- Autoimmune hepatitis
- Neuromyelitis optica
- Nephrotic syndrome
- Acropustulosis
- Membranous glomerulonephritis
- Granulomatosis with polyangiitis
- Interstitial lung disease
- IgA glomerulonephritis
- Bullous pemphigoid
- Graft-versus-host disease
- Delayed graft function
MYHIBBIN is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.
How it works
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Class: immunosuppressive drug
Common side effects
The following adverse reactions are discussed in greater detail in other sections of the label: • Embryofetal Toxicity • Lymphomas and Other Malignancies • Serious Infections • Blood Dyscrasias: Neutropenia, Pure Red Cell Aplasia • Gastrointestinal Complications • Acute Inflammatory Syndrome Associated with…
Who should not take it
MYHIBBIN is contraindicated in patients with a history of hypersensitivity, including anaphylaxis, to mycophenolate mofetil (MMF), mycophenolic acid (MPA), polysorbate 80 (TWEEN) or any other component of the drug product.
Pregnancy and breastfeeding
Use of mycophenolate mofetil (MMF) during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of multiple congenital malformations in multiple organ systems.
Interactions
Brand names
United States
Cellcept
European Union
CellCept · Mycophenolate mofetil Teva · Myfenax
Canada
Ach-Mycophenolate · Ag-Mycophenolate · Apo-Mycophenolate Mofetil · Cellcept · Cellcept I.v. · Jamp-Mycophenolate · Mar-Mycophenolate Mofetil · Sandoz Mycophenolate Mofetil · Spc-Mycophenolate · Teva-Mycophenolate
Other trade names
Arzip · Cellcept hydrochloride
Approval status
- US Food and Drug Administration
- prescription · since 1995
- European Medicines Agency
- authorised · since 1996
- Health Canada
- prescription · marketed
- First approval anywhere
- 1995
Codes
- ATC
- L04AA06
- RxNorm CUI
- 68149
- ChEMBL
- CHEMBL1456
- PubChem CID
- 5281078
- UNII
- 9242ECW6R0
- Wikidata
- Q4567614
Frequently asked questions
What is Mycophenolate mofetil used for?
Mycophenolate mofetil is used for: Lipoid nephrosis, Polymyositis, Myasthenia gravis, Lupus nephritis, Autoimmune hepatitis, Neuromyelitis optica, Nephrotic syndrome, and Acropustulosis.
What kind of medicine is Mycophenolate mofetil?
Mycophenolate mofetil is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Mycophenolate mofetil?
Brand names of Mycophenolate mofetil include Cellcept, CellCept, Mycophenolate mofetil Teva, Myfenax, Ach-Mycophenolate, Ag-Mycophenolate, Apo-Mycophenolate Mofetil, and Cellcept I.v..
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)